Review
doi: 10.1016/j.canlet.2009.04.005.
Epub 2009 May 12.
Cannabinoids in the treatment of cancer
Affiliations
- PMID: 19442435
- DOI: 10.1016/j.canlet.2009.04.005
Item in Clipboard
Review
Cannabinoids in the treatment of cancer
Cancer Lett.
.
Abstract
Cannabinoids, the active components of the hemp plant Cannabis sativa, along with their endogenous counterparts and synthetic derivatives, have elicited anti-cancer effects in many different in vitro and in vivo models of cancer. While the various cannabinoids have been examined in a variety of cancer models, recent studies have focused on the role of cannabinoid receptor agonists (both CB(1) and CB(2)) in the treatment of estrogen receptor-negative breast cancer. This review will summarize the anti-cancer properties of the cannabinoids, discuss their potential mechanisms of action, as well as explore controversies surrounding the results.
Similar articles
-
Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer.Mol Cancer Ther. 2009 Nov;8(11):3117-29. doi: 10.1158/1535-7163.MCT-09-0448. Epub 2009 Nov 3. Mol Cancer Ther. 2009. PMID: 19887554 Free PMC article.
-
Involvement of the CB2 cannabinoid receptor in cell growth inhibition and G0/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212-2 in renal cell carcinoma.BMC Cancer. 2018 May 23;18(1):583. doi: 10.1186/s12885-018-4496-1. BMC Cancer. 2018. PMID: 29792186 Free PMC article.
-
The CB1/CB2 receptor agonist WIN-55,212-2 reduces viability of human Kaposi's sarcoma cells in vitro.Eur J Pharmacol. 2009 Aug 15;616(1-3):16-21. doi: 10.1016/j.ejphar.2009.06.004. Epub 2009 Jun 17. Eur J Pharmacol. 2009. PMID: 19539619
-
The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.J Neuroimmune Pharmacol. 2015 Jun;10(2):255-67. doi: 10.1007/s11481-015-9608-y. Epub 2015 Apr 28. J Neuroimmune Pharmacol. 2015. PMID: 25916739 Free PMC article. Review.
-
Therapeutic potential of cannabinoid receptor ligands: current status.Methods Find Exp Clin Pharmacol. 2006 Apr;28(3):177-83. doi: 10.1358/mf.2006.28.3.985231. Methods Find Exp Clin Pharmacol. 2006. PMID: 16810344 Review.
Cited by
-
Revisiting CB1 receptor as drug target in human melanoma.Pathol Oncol Res. 2012 Oct;18(4):857-66. doi: 10.1007/s12253-012-9515-y. Epub 2012 Mar 24. Pathol Oncol Res. 2012. PMID: 22447182
-
Anticancer and chemosensitization effects of cannabidiol in 2D and 3D cultures of TNBC: involvement of GADD45α, integrin-α5, -β5, -β1, and autophagy.Drug Deliv Transl Res. 2022 Nov;12(11):2762-2777. doi: 10.1007/s13346-022-01137-2. Epub 2022 Feb 25. Drug Deliv Transl Res. 2022. PMID: 35217991 Free PMC article.
-
Therapeutic Cannabis and Endocannabinoid Signaling System Modulator Use in Otolaryngology Patients.Laryngoscope Investig Otolaryngol. 2018 Apr 16;3(3):169-177. doi: 10.1002/lio2.154. eCollection 2018 Jun. Laryngoscope Investig Otolaryngol. 2018. PMID: 30062131 Free PMC article. Review.
-
The tamoxifen derivative ridaifen-B is a high affinity selective CB2 receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effects.Toxicol Appl Pharmacol. 2018 Aug 15;353:31-42. doi: 10.1016/j.taap.2018.06.009. Epub 2018 Jun 12. Toxicol Appl Pharmacol. 2018. PMID: 29906493 Free PMC article.
-
Cancer Initiation, Progression and Resistance: Are Phytocannabinoids from Cannabis sativa L. Promising Compounds?Molecules. 2021 May 2;26(9):2668. doi: 10.3390/molecules26092668. Molecules. 2021. PMID: 34063214 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
